Ambrose Kristen 4

What Happened
Kristen Ambrose, Senior Vice President & Chief Accounting Officer at Vertex Pharmaceuticals (VRTX), was awarded a total of 4,250 performance shares on 2026-01-22 (2,950 shares and 1,300 shares). Each line is an award (transaction code A) recorded at $0.00 per share (no cash paid). These represent earned performance shares from prior PSU grants after the company’s management development and compensation committee certified performance on 01/22/2026.

Key Details

• Transaction date(s) and price(s): 2026-01-22; 2,950 shares @ $0.00 (F1) and 1,300 shares @ $0.00 (F2).
• Total shares awarded: 4,250 performance shares; reported acquisition value = $0.
• Vesting: F1 shares (2,950) will vest on 02/13/2026 (from PSU granted 02/01/2023). F2 shares (1,300) will vest in installments beginning 02/24/2026 (from PSU granted 02/12/2025). Committee certified performance attainment on 01/22/2026.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Filing timeliness: Form 4 filed 2026-01-26 for a 2026-01-22 transaction (filed within the standard two business-day window).
• Transaction type note: Code A = award/grant (not an open-market purchase or sale).

Context
These were performance-based awards (PSUs) that became earned once the company certified goal attainment; they are compensation, not purchases or sales. Such awards increase an insider’s equity but are different from open-market buys (which some investors view as stronger bullish signals). The awards will convert to shares on the listed vesting dates.